cardiology
Heart Failure

SGLT-2 inhibitor ertugliflozin delivers on heart failure

The SGLT-2 inhibitor ertugliflozin reduces the risk of hospitalisation for heart failure (HHF) by 30% compared to placebo in patients with type 2 diabetes and atherosclerotic disease, research shows . The eValuation of ERTugliflozin EffIcacy and Safety CardioVascular Outcomes Trial (VERTIS-CV), presented at the virtual American Diabetes Association 2020 virtual Scientific Sessions, included data from ...

Already a member?

Login to keep reading.


OR
© 2020 the limbic